The worldwide escalation of bacterial resistance to conventional medical antibiotics is a serious concern for modern medicine (4) . In view of this development, the aim of our study was to investigate the antimicrobial and hemolytic properties of silver(I) ions and silver nanoparticles in combination with different antimicrobial peptides (AMPs). The synergistic action of antimicrobial agents can reduce the need for high dosages and minimize side effects (5, 9, 18, 19) . Examples include PGLa plus magainin 2 from Xenopus laevis (18) and ␤-lactam amoxicillin with silver nanoparticles (9) , but a combination of silver nanoparticles or silver ions with AMPs has not been tested. We therefore examined commercial polymyxin B, gramicidin A and alamethicin (from Sigma-Aldrich, Buchs, Switzerland), gramicidin S extracted from Aneurinibacillus migulanus (2) , and PGLa and magainin 2, which was synthesized in our laboratory. All noncommercial peptides were purified on a reverse-phase-high-performance liquid chromatography system to greater than 94%.
The cyclic polycationic lipopeptide polymyxin B is effective against gram-negative bacteria, interacting with lipid A and disrupting their outer membranes (16) . Gramicidin A and alamethicin are hydrophobic and act against gram-positive bacteria by forming ion-selective channels (3) or barrel-stave pores (11), respectively. Gramicidin S is a cyclic ␤-sheet peptide (8), while PGLa and magainin 2 are ␣-helical (12) . They are all cationic and amphipathic and have similar activities against gram-negative and gram-positive bacteria, forming transmembrane pores (12, 14) . In combination with these diverse AMPs, we tested silver nitrate (VWR, Darmstadt, Germany) and silver nanoparticles (mean diameter, 25 nm) stabilized by a nonbiocidal carbon matrix (data not shown) (NovaCentrix, Austin, TX). Electron microscopy demonstrated that these nanoparticles accumulate at both the outer and inner membranes of bacteria (13) . The exact mode of action of silver ions and silver nanoparticles is unknown, but they seem to significantly reduce cellular chemiosmotic potential (6, 10) . Furthermore, it has been reported that within a period of 24 h, less than 5 M of free silver(I) ions are released into solution (13) . Therefore, the antimicrobial effect of silver nanoparticles cannot be attributed to the release of silver(I) ions from the nanoparticles, yet sensitivity to silver may differ for various bacterial strains or when different media are used (15). The MIC is the lowest concentration of a (single) antibiotic that inhibits the visible growth of microorganisms (1) . Assays were carried out in salt-free Luria/Miller-bouillon growth medium for three different gram-positive and six gram-negative bacterial strains. To dissolve silver nanoparticles for the MIC and hemolytic assays, an 8 mM Tris/HCl buffer [pH 7.6] containing 150 mM NaCl was used. Typical MICs, summarized in Table 1 , were around 16 g/ml of PGLa (for both grampositive and gram-negative bacteria) and 1 g/ml of gramicidin A (for gram-positive bacteria only) and polymyxin B (for gramnegative bacteria only). Similar MICs of about 16 g/ml of both silver nitrate and silver nanoparticles were obtained. It is remarkable that the metallic silver nanoparticles and the ionic solution exhibit similar activities at almost the same mass per volume, given that each nanoparticle contains about 650,000 silver atoms. This observation supports the suggestion that the toxicity of the nanoparticles cannot be attributed to the release of free silver ions (see above) (13) .
To detect any synergism between the peptides and silver, a two-dimensional microdilution assay was used (7) . Assays were carried out in salt-free Luria/Miller-bouillon growth medium. The combined antibiotic effect of agents A and B (where A is either AgNO 3 or silver nanoparticles, and B is one of six AMPs) was calculated as follows: the fractional inhibitory con- Table 2 show the following results: polymyxin B acts synergistically with silver nanoparticles against all gram-negative bacteria, while with AgNO 3 it shows synergy only against Escherichia coli, Enterobacter helveticus, and Proteus myxofaciens. In addition, gramicidin S shows synergy with silver nanoparticles against E. helveticus, P. myxofaciens, and Pseudomonas fluorescens, and with AgNO 3 only against E. helveticus. All the other combinations work only in an additive manner. 'Acinetobacter calcoaceticus' was not sensitive to silver nanoparticles even at the highest concentration (1,024 g/ml). We may nevertheless conclude that silver nanoparticles generally show more synergy than silver(I) ion against most strains.
Hemolytic activity was examined using a modified serial dilution assay carried out in 8 mM Tris/HCl buffer [pH 7.6] containing 150 mM NaCl (17) . The ability of AMPs to release hemoglobin from human erythrocytes was measured photometrically at different peptide concentrations. Triton X-100 (Roth, Karlsruhe, Germany) was used to define 100% hemolysis. For every experimental run, the value for autohemolysis was measured and subsequently subtracted from all hemolytic values. All peptides were tested alone and in combination with two different concentrations of AgNO 3 and silver nanoparticles to obtain the AMP concentration (in g/ml) required to induce 50% hemolysis (HC 50 ). It was shown that increasing the concentration of AgNO 3 in combination with any AMP enhances its hemolytic activity (Table 3) . However, the combination of AMPs with silver nanoparticles does not increase hemolysis. In fact, the HC 50 value for the silver nanoparticles on their own could not be determined, as they had low levels of hemolytic activity even at very high concentrations (1,024 g/ml).
Our data thus show that silver nanoparticles together with all antimicrobial peptides tested exhibit at least an additive effect. Genuine synergy was observed when silver nitrate and silver nanoparticles were used together with polymyxin B and gramicidin S. The combination of silver nanoparticles and polymyxin B showed the most pronounced antibiotic synergy against gram-negative bacteria. The nanoparticles also exhibited a remarkably low level of hemolytic activity, unlike AgNO 3 . The combination of silver nanoparticles with polymyxin B is thus a promising candidate for a new treatment for infections caused by gram-negative pathogens. Mechanistically, it appears that permeabilization of the outer bacterial membrane by polymyxin B enhances the intrinsic antibiotic effect of the silver nanoparticles.
